| GTO ID | GTC3289 |
| Trial ID |
NCT05666700
|
| Disease |
Multiple Myeloma
|
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Carvykti|Ciltacabtagene Autoleucel|Cilta-cel|JNJ-68284528 |
| Location approved | US, EU, UK, Japan, Australia, Canada |
| Generation | 2nd |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study |
| Year | 2022 |
| Country | Australia |
| Company sponsor | Peter MacCallum Cancer Centre, Australia |
| Other ID(s) | 21/015 |